- /
- Supported exchanges
- / US
- / RHHBF.OTCQX
Roche Holding AG (RHHBF OTCQX) stock market data APIs
Roche Holding AG Financial Data Overview
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Roche Holding AG (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Roche Holding AG data using free add-ons & libraries
Get Roche Holding AG Fundamental Data
Roche Holding AG Fundamental data includes:
- Net Revenue: 62 959 M
- EBITDA: 23 964 M
- Earnings Per Share: 19
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-04-21
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roche Holding AG News
New
Nurix Therapeutics falls 2% following Q3 earnings as operating expenses up
Investing.com -- Nurix Therapeutics Inc (NASDAQ:NRIX) reported third quarter fiscal 2026 financial results on Monday, with revenue of $673.1 million, up significantly from $7.9 million in the same qua...
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nurix Therapeutics, Inc. Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combinati...
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA
Roche RHHBY has reported encouraging one-year data from two phase III studies evaluating investigational vamikibart for uveitic macular edema (UME), a sight-threatening inflammatory eye condition. Th...
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Shares of Moderna MRNA, BioNTech BNTX and Novavax NVAX rose on Friday after a New York Times (NYT) report detailed a planned National Institutes of Health (NIH)-backed initiative to accelerate the de...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.